Aleksandra Zivkovic Selected Research

7a- (4- octylphenethyl)tetrahydro- 1H- oxazolo(3,4- c)oxazole

1/2016	Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments.
10/2014	Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aleksandra Zivkovic Research Topics

Disease

3	Neoplasms (Cancer) 01/2022 - 02/2012
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 10/2014
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2022 - 05/2017
2	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 05/2017
2	Inflammation (Inflammations) 01/2022 - 05/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2021 - 03/2018
2	Multiple Sclerosis 01/2021 - 10/2014
2	Autoimmune Diseases (Autoimmune Disease) 09/2020 - 10/2014
2	Pain (Aches) 04/2020 - 06/2015
2	Relapsing-Remitting Multiple Sclerosis 01/2016 - 10/2014
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Leukemia 01/2022
1	Narcolepsy 01/2021
1	Cognitive Dysfunction 01/2021
1	Encephalomyelitis (Myeloencephalitis) 09/2020
1	Asthma (Bronchial Asthma) 04/2020
1	Obesity 04/2020
1	Parkinson Disease (Parkinson's Disease) 03/2018
1	Metabolic Diseases (Metabolic Disease) 08/2015
1	Neuralgia (Stump Neuralgia) 06/2015
1	Wounds and Injuries (Trauma) 06/2015
1	Heart Arrest (Cardiac Arrest) 07/2013
1	Myocardial Stunning (Stunned Myocardium) 07/2013
1	Takotsubo Cardiomyopathy 07/2013

Drug/Important Bio-Agent (IBA)

5	Fingolimod Hydrochloride (FTY720)FDA Link 01/2021 - 10/2014
3	LigandsIBA 09/2020 - 03/2018
2	Histamine H3 Receptors (Histamine H3 Receptor)IBA 12/2021 - 01/2021
2	Pharmaceutical PreparationsIBA 01/2021 - 01/2016
2	Sphingosine-1-Phosphate ReceptorsIBA 01/2021 - 06/2015
2	CeramidesIBA 05/2017 - 02/2012
2	7a- (4- octylphenethyl)tetrahydro- 1H- oxazolo(3,4- c)oxazoleIBA 01/2016 - 10/2014
1	dihydroceramide desaturaseIBA 01/2022
1	Ether (Diethyl Ether)IBA 01/2022
1	c-Mer Tyrosine KinaseIBA 01/2022
1	PhosphatidylserinesIBA 01/2022
1	CDPdiacylglycerol-Serine O-PhosphatidyltransferaseIBA 01/2022
1	piperidineIBA 01/2021
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2021
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2021
1	pitolisantIBA 01/2021
1	MorpholinosIBA 09/2020
1	siponimodIBA 09/2020
1	AntigensIBA 09/2020
1	imidazoleIBA 04/2020
1	Monoamine Oxidase (MAO)IBA 03/2018
1	indacrinoneIBA 03/2018
1	sphingosine kinaseIBA 01/2016
1	TubulinIBA 08/2015
1	ResveratrolIBA 08/2015
1	FTY 720PIBA 06/2015
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2015
1	7a- (4- (heptyloxy)phenethyl)tetrahydro- 1H- oxazolo(3,4- c)oxazoleIBA 10/2014
1	OxazolesIBA 10/2014

Therapy/Procedure

2	Immunotherapy 01/2022 - 05/2017
2	Cell Transplantation 01/2022 - 05/2017
1	Drug Therapy (Chemotherapy) 06/2015
1	Therapeutics 10/2014
1	General Anesthesia 07/2013